Objetivo Prostate cancer (PC) is one of the deadliest types of cancer in males worldwide. Early stage PC is often curable but many patients develop castration-resistant prostate cancer (CRPC), resulting in lethal end-stage disease. Prostate specific antigen (PSA) plasma levels have been traditionally exploited for diagnosis and prognosis. However, the application of PSA as a biomarker is associated with predictability issues. Advanced therapies are required for the treatment of CRPC, guided by a reliable companion diagnostic (CDx) test to monitor therapeutic efficacy. The aim of “PREVENT” is to co-develop a nanomedicine-based combination therapy for the treatment of CRPC and a CDx based on extracellular vesicles (EVs). I will employ tumour-targeted nanomedicines to deliver more drug to the tumour and reduce side effects when compared to free drug. The treatment comprises microfluidics-prepared lipid nanoparticles (LNPs) containing siRNAs that target genes involved in CRPC and LNPs loaded with the cytotoxic anti-cancer agent docetaxel to achieve synergistic therapeutic effects. For the CDx test, extracellular vesicles (EVs) have created excitement as possible biomarker candidates. EVs are released by cells as means of intercellular communication and can be detected in bodily fluids. The number of EVs and their composition is altered in CRPC, raising opportunities to exploit them in a CDx test. As EVs provide a fingerprint of their parental cell, EVs can be considered liquid biopsies, providing more information than standard biomarker measurements, and much less invasive than prostate biopsies. I will collect blood and urine samples during the preclinical evaluation of the proposed treatment for analysis using immunocapture and flow cytometry-based immunodetection platforms. The co-development of a nanomedicine combination treatment for CRPC and a CDx test is a rational strategy that has the potential to advance into clinical evaluation and ultimately improve patient survival. Ámbito científico medical and health sciencesclinical medicineoncologyprostate cancernatural sciencesbiological sciencescell biologynatural sciencesbiological sciencesbiochemistrybiomoleculeslipidsmedical and health sciencesmedical biotechnologynanomedicineengineering and technologynanotechnologynano-materials Palabras clave Castration resistant prostate cancer nanomedicine targeted drug delivery combination treatment RNAi docetaxel extracellular vesicles biomarker companion diagnostic test Programa(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Tema(s) MSCA-IF-2014-GF - Marie Skłodowska-Curie Individual Fellowships (IF-GF) Convocatoria de propuestas H2020-MSCA-IF-2014 Consulte otros proyectos de esta convocatoria Régimen de financiación MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF) Coordinador UNIVERSITAIR MEDISCH CENTRUM UTRECHT Aportación neta de la UEn € 228 421,80 Dirección HEIDELBERGLAAN 100 3584 CX Utrecht Países Bajos Ver en el mapa Región West-Nederland Utrecht Utrecht Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 228 421,80 Socios (1) Ordenar alfabéticamente Ordenar por aportación neta de la UE Ampliar todo Contraer todo Socio Las organizaciones asociadas contribuyen a la aplicación de la acción, pero no firman el acuerdo de subvención. UNIVERSITY OF BRITISH COLUMBIA Canadá Aportación neta de la UEn € 0,00 Dirección AGRONOMY ROAD 102-6190 V6T1Z1 Vancouver Ver en el mapa Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 145 622,40